Product image of Mvabea (Modified Vaccinia Ankara - Bavarian Nordic Virus Encoding The Ebola Virus Zaire Mayinga Strain Glyco) supplied by GNH India

Mvabea

Active Ingredient:
Modified Vaccinia Ankara - Bavarian Nordic Virus Encoding The Ebola Virus Zaire Mayinga Strain Glyco
Origin:
EU

Mvabea (Modified Vaccinia Ankara - Bavarian Nordic Virus Encoding The Ebola Virus Zaire Mayinga Strain Glyco)

Modified Vaccinia Ankara - Bavarian Nordic virus encoding Ebola virus Zaire Mayinga strain glycoprotein, the active ingredient in Mvabea, is a vaccine presented as a sterile injectable for intramuscular use. It is designed to prevent Ebola virus disease caused by the Zaire strain in individuals at risk of exposure.

GNH India supplies Mvabea as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies, and clinics worldwide, with established cold‑chain logistics and regulatory support for global distribution, ensuring product integrity and timely delivery to end‑users.

Manufacturer / TM Owner

Janssen-Cilag International Nv

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Mvabea is a recombinant viral vector vaccine that targets the Ebola virus Zaire strain and is used for prophylaxis in at‑risk populations.

  • Ebola virus disease (Zaire strain) prevention: induces immunity to protect against infection.
  • Healthcare workers in outbreak zones: reduces occupational risk of Ebola acquisition.
  • Travelers to endemic regions: provides pre‑exposure protection against Ebola virus.

How It Works

  • Mvabea uses a recombinant Modified Vaccinia Ankara (MVA) vector that has been engineered to express the glycoprotein of the Ebola virus Zaire Mayinga strain. After intramuscular injection, the vector infects host cells, producing the viral glycoprotein, which stimulates both humoral (antibody) and cellular (T‑cell) immune responses, thereby establishing protective immunity against Ebola virus infection.

Side Effects

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or swelling: localized erythema or edema.
  • Fever: transient low‑grade temperature rise.
  • Headache: mild to moderate headache within 24‑48 hours.
  • Fatigue: temporary feeling of tiredness.
  • Myalgia: muscle aches after vaccination.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare neurologic disorder with progressive weakness.
  • Severe thrombocytopenia: marked drop in platelet count.
  • High‑grade fever >39 °C: prolonged febrile response.
  • Seizures: uncommon convulsive episodes.
  • Disseminated intravascular coagulation: rare clotting disorder.

Precautions & Warnings

Before administration, consider the following precautions:

  • Contraindication assessment: avoid in individuals with known severe allergic reaction to any vaccine component.
  • Immunocompromised patients: evaluate risk‑benefit as immune response may be reduced.
  • Acute illness: defer vaccination if the person has a moderate or severe febrile illness.
  • Pregnancy and lactation: discuss potential risks with a qualified health professional.
  • Age restrictions: follow local regulatory guidance for eligible age groups.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Vaccines may interact with other agents that affect the immune system.

Major Interactions (Avoid)

  • Live attenuated vaccines administered concurrently: may interfere with immune response to Mvabea.
  • High‑dose immunoglobulin therapy given within 4 weeks: can diminish vaccine efficacy.

Moderate Interactions (Monitor Closely)

  • Immunosuppressive drugs (e.g., corticosteroids, chemotherapy): may reduce immunogenicity.
  • Antipyretics taken prophylactically: may blunt antibody response if used before vaccination.
  • Antihistamines: may mask early allergic signs; monitor patient closely after injection.

Frequently Asked Questions

Mvabea is a recombinant vaccine indicated for the prevention of Ebola virus disease caused by the Zaire strain. It is administered to individuals who may be exposed to the virus, such as healthcare workers in outbreak areas or travelers to endemic regions, to stimulate protective immunity.

The Modified Vaccinia Ankara (MVA) vector in Mvabea has been engineered to express the glycoprotein of the Ebola Zaire Mayinga strain. After intramuscular injection, the vector delivers this protein to host cells, prompting the immune system to produce antibodies and T‑cell responses that recognize and neutralize the actual Ebola virus.

The dosing regimen for Mvabea is determined by the prescribing clinician based on current guidelines, the individual's risk profile, and local regulatory recommendations. Healthcare providers set the exact dose, schedule, and any booster requirements.

Safety data for Mvabea in pregnant or lactating individuals are limited. Healthcare professionals should weigh the potential benefits of protection against Ebola exposure against any unknown risks, and discuss the decision with the patient before administration.

To place an order, submit an enquiry on the Mvabea product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details, and necessary import documentation.

Mvabea uses a non‑replicating Modified Vaccinia Ankara vector, whereas other licensed Ebola vaccines may employ different platforms such as recombinant vesicular stomatitis virus or adenoviral vectors. The MVA platform is known for a strong safety profile and does not replicate in human cells, which can be advantageous for immunocompromised populations.

Mvabea must be stored refrigerated at 2 °C to 8 °C. It should be kept in its original packaging, protected from light, and must never be frozen or shaken. Maintaining the cold chain is essential to preserve vaccine potency.

Mvabea is given as a single intramuscular injection, typically into the deltoid muscle. The administration is performed by a qualified healthcare professional using aseptic technique. Post‑vaccination observation for a short period is recommended to monitor for immediate reactions.

The most serious adverse events reported with Mvabea include severe allergic reactions such as anaphylaxis, rare neurologic disorders like Guillain‑Barré syndrome, and, very rarely, severe thrombocytopenia or disseminated intravascular coagulation. Prompt medical attention is required if any of these occur.

Mvabea is contraindicated in individuals with a known severe allergy to any component of the vaccine. Caution is advised for those with severe immunodeficiency, uncontrolled acute illness, or who are pregnant or breastfeeding without a clear risk‑benefit assessment by a healthcare provider.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Modified Vaccinia Ankara - Bavarian Nordic Virus Encoding The Ebola Virus Zaire Mayinga Strain Glyco

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT